Northeast Private Client Group, a real estate investment sales firm based in Shelton, recently promoted Robert Paterno to senior associate.
Paterno joined the firm’s Connecticut office in 2018.
In his new position, Paterno will establish and maintain client relationships, advise clients on market conditions and underwriting, and facilitate the investment sales process.
Bradley Balletto, the firm’s senior vice president, investments, said in an announcement, “Bob’s hard work and commitment to growing his and the team’s business is evident and admirable, and I fully expect more of this in the future.”
The firm specializes in mixed-use, retail, and multifamily real estate, and it represents investors, property owners, and professional real estate investors.
*****
Sacred Heart names new theater development director
Fairfield-based Sacred Heart University’s new director of development for its SHU Community Theatre is Laurel Lea.
Lea, a Redding resident, will guide a philanthropic plan for the theater and develop
sponsorship and membership packages. She will also help it meet its fundraising goals.
Located in downtown Fairfield, the SHU Community Theatre is a historic, 400-seat venue. It hosts a variety of events, from live concerts to plays and film screenings.
Lea previously served as manager of sponsorship and development at Ridgefield Playhouse, a 500-seat regional performing-arts venue, and director of development at Norwalk’s Wall Street Theater, a 700-seat facility.
*****
Arvinas picks new chief commercial officer
Arvinas Inc., a New Haven-based, clinical-stage biotech focused on fighting prostate and breast cancer, recently hired John Northcott to serve in its newly-created position of chief commercial officer.
President and CEO John Houston called Northcott an “excellent addition” to the company’s leadership team.
“I am confident that his experience and impressive product development and commercialization track record will play an important role in Arvinas’ growth as we continue to advance our pipeline and expand our portfolio,” Houston said.
Northcott has a background in developing and commercializing products, such as the drugs Avastin and Imbruvica. He has worked for companies such as Nektar Therapeutics, Pharmacyclics, Lexicon Pharmaceuticals, Genentech, Pfizer and Merck.
